nnd-502 and Dermatitis--Contact

nnd-502 has been researched along with Dermatitis--Contact* in 1 studies

Other Studies

1 other study(ies) available for nnd-502 and Dermatitis--Contact

ArticleYear
Contact Dermatitis Caused by Efinaconazole and Luliconazole.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2021, Jun-30, Volume: 88, Issue:3

    We report a case of contact dermatitis caused by both efinaconazole, a topical triazole antifungal drug, and luliconazole, a topical imidazole antifungal drug. Positive patch test reactions were observed with efinaconazole and luliconazole. A patch test with lanoconazole also elicited a positive reaction. We hypothesized that structural similarity between luliconazole and lanoconazole led to cross-reaction, and that the dithiolane ring common to both drugs or the structure of the vinyl imidazole with a dithiolane ring could be the antigenic determinant. Since efinaconazole and luliconazole have no common structures, patients could be sensitized to both drugs separately. The antigenic determinant of efinaconazole is unknown. However, the chemical formula of ravuconazole, an oral triazole antifungal drug, is similar to that of efinaconazole. Clinicians should carefully consider potential cross-reactivity between these drugs.

    Topics: Administration, Topical; Aged; Antifungal Agents; Dermatitis, Contact; Epitopes; Foot Dermatoses; Humans; Imidazoles; Male; Patch Tests; Triazoles

2021